logo
  

Eiger Announces Positive Phase 2 Results Of Avexitide In Congenital Hyperinsulinism

Eiger BioPharmaceuticals, Inc. (EIGR) announced a presentation of positive phase 2 study results of Avexitide in congenital hyperinsulinism. Avexitide infusion demonstrated significant reductions in glucose infusion requirements to maintain euglycemia or normal glucose levels in neonates and infants. Avexitide represents a promising, targeted approach for the treatment of congenital hyperinsulinism.

Avexitide is a targeted, first-in-class, GLP-1 antagonist in development for the treatment of hyperinsulinism, an ultra-rare, life-threatening, pediatric disorder of persistent hypoglycemia that results in irreversible brain damage in up to 50% of children.

Avexitide 100, 200 and 1,000 pmol/kg/min ascending doses demonstrated 1.3 (15%), 2.9 (24%), and 4.3 (56%) mg/kg/min reductions in glucose infusion rate relative to placebo, respectively, and entirely abolished the glucose requirement in 50% of patients at the top dose.

Avexitide was well-tolerated in this study. Adverse events were typically mild in severity and transient, and there were no serious adverse events.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Despite fears of inflation, consumers spent $9.12 billion for online shopping during Black Friday, higher than in previous years, as per a report published by Adobe Analytics. During the 2022 holiday season, total estimated revenues are $209.7 billion, a growth of 2.5 percent from last year's recorded revenues of $205 billion. Weis Markets, Inc., a Mid Atlantic food retailer, has recalled 108 containers of Weis Quality Sea Salt Caramel Ripple Ice Cream citing possible presence of undeclared soy and coconut allergens, the U.S. Food and Drug Administration said. The recalled product comes in 48oz containers that says Weis Quality Sea Salt Caramel Ripple Ice Cream, while the lid says Weis Quality Caramel Caribou Ice Cream Amazon.com Inc. plans to spend more than $1 billion annually to produce movies that will get a theatrical release, Bloomberg reported, citing people familiar with the matter. The online retailer giant, which acquired movie maker MGM Studios earlier this year for $8.45 billion, is likely to produce between 12 and 15 movies each year for movie theaters.
RELATED NEWS
Follow RTT